Lupus nephritis in the XXI century

Cover Page

Cite item

Full Text

Abstract

Lupus nephritis (LN) is the most common organ lesion in systemic lupus erythematosus (SLE), developing in 40–50% of patients. Due to immunosuppressive therapy, the survival of patients with SLE has increased significantly over the past 50 years, and the proportion of severe kidney damage in the death structure has decreased. However, LN relapses and complications of immunosuppression, accelerated atherogenesis, concomitant diseases lead to the accumulation of organ damage and an increased risk of death. The article consideres the place of kidney damage in the SLE, the risk factors for LN development, the main renal histopathological changes, it identifies a number of issues that need to be addressed to optimize treatment and improve LN long-term outcomes, including, the revision of pathogenetic therapy regimens with restriction of glucocorticosteroids and prescribing drugs with steroid-sparing activity, the integration of new drugs for LN treatment, wider use of modern nephroprotection capabilities.

About the authors

Irina N. Bobkova

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: irbo.mma@mail.ru
ORCID iD: 0000-0002-8007-5680

д-р мед. наук, проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Sergey V. Moiseev

Sechenov First Moscow State Medical University (Sechenov University)

Email: irbo.mma@mail.ru
ORCID iD: 0000-0002-7232-4640

акад. РАН, д-р мед. наук, проф., проф. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского, дир. Клиники ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3

Russian Federation, Moscow

Lidia V. Lysenko

Sechenov First Moscow State Medical University (Sechenov University)

Email: irbo.mma@mail.ru
ORCID iD: 0000-0002-1166-7308

д-р мед. наук, проф., зав. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Elena S. Kamyshova

Sechenov First Moscow State Medical University (Sechenov University)

Email: irbo.mma@mail.ru
ORCID iD: 0000-0002-1823-0125

канд. мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

References

  1. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-23. doi: 10.1136/annrheumdis-2020-216924
  2. Hanly JG, O'Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-62. doi: 10.1093/rheumatology/kev311
  3. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020;76(2):265-81. doi: 10.1053/j.ajkd.2019.10.017
  4. Kon T, Yamaji K, Sugimoto K, et al. Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. Mod Rheumatol. 2010;20(2):168-77. doi: 10.1007/s10165-009-0260-3
  5. Borchers AT, Leibushor N, Naguwa SM, et al. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174-94. doi: 10.1016/j.autrev.2012.08.018
  6. Rovin BH, Parikh SV, Alvarado A. The kidney biopsy in lupus nephritis: is it still relevant? Rheum Dis Clin North Am. 2014;40(3):537-ix. doi: 10.1016/j.rdc.2014.04.004
  7. Остапенко В.М. Из истории изучения системной красной волчанки (вклад академика АМН СССР Е.М. Тареева и его клинической школы). Научно-практическая ревматология. 2004;42(1):94-7 [Ostapenko V.M. From history of systemic lupus erythematosus study (Contribution of E.M. Tareev and his clinical school). Rheumatology Science and Practice. 2004;42(1):94-7 (in Russian)].
  8. Основы нефрологии. Под ред. Е.М. Тареева. М.: Медицина, 1972. Т. 2; с. 595-634 [Osnovy nefrologii. Pod red. EM Tareeva. Moscow: Meditsina, 1972. T. 2; s. 595-634 (in Russian)].
  9. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-35. doi: 10.2215/CJN.05780616
  10. Моисеев С.В., Новиков П.И., Буланов Н.М. Системная красная волчанка: эпидемиология, отдаленные исходы и бремя болезни. Клин. фармакология и терапия. 2021;30(4):13-22 [Moiseev S, Novikov P, Bulanov N. Systemic lupus erythematosus: epidemiology, outcomes and burden. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2021;30(4):13-22 (in Russian)]. DOI:10.32756/ 0869-5490-2021-4-13-22
  11. Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515-32. doi: 10.1038/s41584-021-00668-1
  12. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest. 1996;97(5):1348-54. doi: 10.1172/JCI118552
  13. Munroe ME, James JA. Genetics of Lupus Nephritis: Clinical Implications. Semin Nephrol. 2015;35(5):396-409. doi: 10.1016/j.semnephrol.2015.08.002
  14. Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clin Immunol. 2017;185:32-9. doi: 10.1016/j.clim.2016.09.012
  15. Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol. 2019;31(6):682-8. doi: 10.1097/BOR.0000000000000642
  16. Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76(12):2009-16. doi: 10.1136/annrheumdis-2017-211663
  17. Moroni G, Vercelloni PG, Quaglini S, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis. 2018;77(9):1318-25. doi: 10.1136/annrheumdis-2017-212732
  18. Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016;68(6):1432-41. doi: 10.1002/art.39594
  19. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-30. doi: 10.1111/j.1523-1755.2004.00443.x
  20. Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):281-95. doi: 10.1016/j.kint.2018.11.008
  21. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-96. doi: 10.1016/j.kint.2017.11.023
  22. Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol. 2017;29(3):241-7. doi: 10.1097/BOR.0000000000000381
  23. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-31. doi: 10.1002/art.10461
  24. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-12. doi: 10.1681/ASN.2008101028
  25. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46(4):995-1002. doi: 10.1002/art.10142
  26. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-9. doi: 10.1136/ard.2010.131995
  27. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-95. doi: 10.1056/NEJMoa1014460
  28. Shin JI, Li H, Park S, et al. Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses. J Clin Med. 2022;11(2):343. doi: 10.3390/jcm11020343
  29. Bankole AA, Nwaonu JN. The Shifting Landscape of Lupus Nephritis Management: A Review. Cureus. 2022;14(1):e20950. doi: 10.7759/cureus.2095
  30. Morales E, Galindo M, Trujillo H, Praga M. Update on Lupus Nephritis: Looking for a New Vision. Nephron. 2021;145(1):1-13. doi: 10.1159/000511268

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies